Investors Urged to Join Class Action Against Actinium Pharmaceuticals for Alleged Securities Fraud

In a recent announcement, the Rosen Law Firm, renowned for defending investor rights, revealed the initiation of a class action lawsuit targeting Actinium Pharmaceuticals, Inc. (NYSE American: ATNM). This legal action focuses on those who purchased Actinium securities between October 31, 2022, and August 2, 2024.

Details of the Class Action

This lawsuit claims that during the specified period, misleading statements were made by company executives regarding the viability of the company's treatments, specifically related to Actinium's Iomab-B Biologics License Application, which underwent an FDA review. Investors are encouraged to come forward, especially those who wish to assume the role of lead plaintiff in this case. The deadline to initiate this filing is May 26, 2025.

Why Participate?

Those who have acquired securities from Actinium during the class period may be eligible for compensation without incurring any fees upfront, thanks to a contingency fee agreement that the Rosen Law Firm offers. By participating in this class action, investors could collectively address grievances resulting from the alleged fraudulent activity.

The firm encourages potential plaintiffs to ensure their legal representation aligns with professionalism and a successful track record. With a long history of handling securities class actions and achieving substantial settlements for their clients, the Rosen Law Firm stands as a recommended choice for those looking to navigate this complex legal landscape.

Case Allegations

The focus of the lawsuit revolves around claims that Actinium Pharmaceuticals made false statements and withheld crucial information regarding their clinical trial data. According to the allegations, the findings from the Sierra Trial were unlikely to meet the FDA's rigorous standards for drug approval, and these discrepancies led to misleading public perceptions about the company’s future prospects and operational integrity.

Specifically, it is alleged that:
1. The Sierra Trial data was not likely to fulfill FDA guidelines necessary for the acceptance and approval process of the Iomab-B application.
2. Additional analyses provided to the FDA to counteract negative trial outcomes were deemed inadequate.
3. The likelihood of the FDA refusing to review the application or granting approval was understated in public disclosures.
4. Consequently, positive claims regarding Actinium's business ventures were materially misleading.

Next Steps for Investors

For investors interested in joining the class action, you can sign up by visiting the Rosen Law Firm’s website or contacting their offices directly. The attorneys at the firm underscore that currently no class has been certified, meaning that until this occurs, participating individuals need to assert their representation.

Engaging in this lawsuit could pave the way for justice for those affected by the alleged securities fraud, allowing investors to seek reparations for their financial losses. It’s crucial for anyone affected to act swiftly and seek appropriate legal counsel.

For further inquiries, the Rosen Law Firm provides various contact methods, including a dedicated phone line and email for interested parties. Stay updated by following the firm's activities on their social media platforms.

As a reminder, past successes do not guarantee future outcomes, and potential participants should evaluate their options carefully before joining the class action.